Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study

• Published in: Surgical and experimental pathology Vol. 2; no. 1; pp. 1 - 13
• Main Authors: Harb, Ola A., Kaf, Randa Mohamed, Taha, Heba F., Ahmed, Rham Z., Mandour, Doaa, Al Attar, Ahmed Z., Fathy, Ayman, Almoregy, Abdelwahab S., Osman, Gamal, Gertallah, Loay M.
• Format: Journal Article
• Language: English
• Published: London BioMed Central 01.06.2019; BMC
• Subjects: Antibodies; Apoptosis; Breast cancer; Cell death; Cervix; DLBCL; FOXP-1; Gene expression; Immunohistochemistry; Ligands; Lymphoma; Medical prognosis; Medical research; Medicine; Oncology; Pathology; PD-L1; Prognosis; Signal transduction; Stains & staining; STAT-3; Statistical analysis; Transcription factors; United States > US
• ISSN: 2520-8454; 2520-8454
• DOI: 10.1186/s42047-019-0038-7

Abstract Context PD-L1 is an inhibitory ligand that functions as an essential immune checkpoint. FOXP-1 is a member of the FOXP family. STAT-3 plays a critical role in regulation of cell proliferation and survival. The detailed expression of the three markers together in DLBCL tissues and their prognostic value in patients with DLBCL were not fully investigated. Aim was to assess the expression of PD-L1, FOXP-1 and STAT-3 in diffuse large B-cell lymphoma (DLBCL) and to correlate their expression with the pathological findings, prognostic parameters and clinical implications of patients. Methods PD-L1, FOXP-1 and STAT-3 were assessed in DLBCL tissues derived from 50 patients using immunohistochemistry. Patients were followed up for 3 years for response to therapy progression, recurrence and survival. Results High PD-L1 expression was associated with bone marrow involvement ( p  = 0.004), extra-nodal involvement ( p  = 0.006) and advanced stage ( p  = 0.003). High FOXP-1 expression was associated with presence of bone marrow involvement and high risk group ( p  < 0.001). High STAT-3 expression was associated with older age of the patient (p < 0.001), presence of bone marrow involvement ( p  = 0.002), extra-nodal involvement ( p  = 0.009), and high risk group ( p  = 0.005). High expression of PD-L1, FOXP-1 and STAT-3 was related to poor response to therapy, poor OS rate and RFS rates ( p  < 0.001). Conclusion High expression of PD-L1, FOXP-1 and STAT-3 was related poor prognosis in DLBCL patients.